[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
Last Monday, Richter sent the first remdesivir package to seven Hungarian health institutions. Several patients have already received it. Meanwhile, they are working on production continuously, currently Richter has already produced 15,000 batches of small bottles.
The development of the drug and its turn through the supply chain proceeded at record speed on the basis of an existing basic concept, the project was implemented from hundreds of millions of guilders. In such an environment, the development and production of drugs under the roof of a company takes place in a company, said Gábor Orbán. This is not the case in many parts of the world. Richter, by the way, has never produced as many drugs as this year, they never had as much stock as this year.
Remdesivir was originally developed for Ebola and should not be marketed for testing purposes only. In addition to remdesivir, therapeutic solutions for other coronaviruses are also being developed. They had three such projects, two biological and favipirapir. They also agree to vaccinate an American company, but Richter is not developing the vaccine.
Regarding vaccines, Gábor Orbán said that logistically it will not be easy to carry out mass vaccination, currently the debate in the world is whether the rich countries should receive the vaccine or the poorest ones. According to the Bill Gates Foundation, it is advisable to start vaccination in countries with poorer health systems.
Richter’s drug sales statistics show that some interventions, such as plastic interventions or infertility treatment, have an increase in antiviral drugs, flu drugs, and contraceptives.
Gábor Orbán said about the Ukrainian market: half of them still have their turnover, as before the events of 2014. In Russia, however, the peak was in 2013. Richter’s ambition is to diversify into areas with higher growth potential such as Western Europe or the United States. Today, Richter expects growth abroad primarily from gynecological products. By the way, there are preparations that cost between 7 and 8 times the price compared to the European level. Richter’s largest market became the United States in the middle of the year. In the past, the company had the largest domestic, Russian and Chinese markets. Now the Russian is the second, the third is domestic.
Gábor Orbán declined to comment on the expected evolution of the company’s share prices.
[ad_2]
